Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Vyndaqel (tafamidis)
pCPA File Number:
21191
Negotiation Status:
Concluded with an LOI
Indication(s):
transthyretin-mediated amyloidosis
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
SR0625-000
pCPA Engagement Letter Issued:
2020-06-10
Negotiation Process Concluded:
2021-02-04